Pfizer Corporation

Pfizer Products Inc.

Allen Jacob Duplantier

Chakrapani Subramanyam

Louis Stanley Chupak

Mark Anthony Dombroski

Anthony John Milici

Wan F Lau

Mark A Dombrowski

Anthony Marfat

Michael Anthony Letavic

James F Eggler

Ellen Ruth Laird

Kelvin Cooper

Edward F Kleinman

Kim F McClure

Robert James Chambers

Hiroko Masamune

Victoria Lee Cohan

John B Cheng

John W Watson

The present invention provides benzamide inhibitors of the P2Xreceptor of the formula: wherein R-Rare as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

[object Object]

The present invention relates to novel to P2Xinhibitors of formula I and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are potent inhibitors of P2Xand as such are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Benzamide, heteroarylamide and reverse amides

The present invention provides benzamide inhibitors of the P2Xreceptor of the formula: wherein R&#x2013;Rare as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

The present invention provides benzamide inhibitors of the P2Xreceptor of the formula:  wherein R&#x2013;Rare as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

The present invention provides benzamide inhibitors of the P2Xreceptor of the formula:wherein R-Rare as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Benzamide inhibitors of the P2X7 Ereceptor

The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formmula I:and to processs for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are useful in the treatment of inflammation, osteoarthritis, rhematoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

N-alkyl-adamantyl triazinyl benzamide derivatives

There is disclosed a genus of non-peptidyl compounds, wherein said compounds are VLA-4 inhibitors useful in treating inflammatory, autoimmune, and respiratory diseases, and wherein said compounds comprise a compound of Formula (1.0.0):

Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases

Triazolo-pyridines anti-inflammatory compounds

A compound of formula (I) wherein m, n, o, p, q, r, A, B, D, E, R , R ,R , R , R , R , R and R are as defined in the description, useful in the treatment of respiratory, allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

Growing community of inventors

Ledyard, CT, United States of America

Allen Jacob Duplantier